In this review, we discuss the biology and development of CD8+ Tregs, their contribution to reducing GVHD while preserving GVL effects apart from CD4+ Tregs as well as their heterogeneity, focusing on questions and future improvements through genetic technologies. Here, CD8A is linked to graft versus host disease.